Gapping up
In reaction to strong earnings/guidance:
- NSM +13.4%, CHS +9.4%, NWHM +9.1%, GRMN +8.6%, RRGB +8.4%, DEPO +7.2%
- LNTH +7%, (also LNTH and GE Healthcare sign a a term sheet relating to the continued Phase III development and commercialization of flurpiridaz F 18)
- XPO +6.1%, CYD +5.9%, TOL +5.5%, WMGI +5.4%, VMI +5%, VRSK +4.5%, DL +4.3%, HCKT +4.2%, LYG +3.5%, SRT +3.4%, HCLP +3.2%, SBGI +2.7%
- JELD +2.2%, EXR +2%, AWK +1.8%, GEO +1.8%, LZB +1.7%, NCLH +1.7%, SPN +1.6%, HFC +1.5%, UVE +1.4%, WCN +1.1%, MIC +1.1%, DISH +1.1%, NM +1%
M&A news:
- UL +2.3% (says conducting a comprehensive review of options available to accelerate delivery of value for the benefit of its shareholders)
- UN +1.8%
Other news:
- DCTH +23.5% (announces publication of a review of investigational PHP with Melphalan/HDS in the American Journal of Clinical Oncology)
- NVDQ +20.3% (continued strength after confirming Cigna now covers Dermacell for breast reconstruction surgery and Dermacell AWM for diabetic foot ulcers)
- MBOT +17% (announces the USPTO has issued a Notice of Allowance for a technology patent covering a device for the prevention of shunt stenosis)
- CUR +7.2% (announces that U.S. Patent for NSI-189)
- JAGX +6.5% (continued strength following yesterday's 11.5% move higher)
- ALIM +5.6% (Alimera Sciences and Knight Therapeutics announce that Knight's New Drug Submission for ILUVIEN has been accepted for review by Health Canada)
- EGY +4.4% (very light volume; reports year-end 2016 proved reserves of 2.6 MMBOE and reserves replacement of 87% of 2016 production in Gabon)
- TRCO +3% (Starboard Value discloses 6.6% active stake)
- ERIC +1.9% (Verizon Enterprise Solutions selected ERIC to provide enabling technologies for its virtualized global Managed Network Services offerings)
- ALLT +1.2% (has been selected by Telefonica (TEF) to provide network-based security services)
Analyst comments:
- SRRA +6.4% (upgraded to Outperform at Wedbush)
- STNG +4.7% (upgraded to Buy from Hold at ABN Amro)
- STM +2% (upgraded to Overweight from Equal Weight at Barclays)
- EXAS +1.6% (upgraded to Buy from Neutral at ROTH Capital)
- AMD +1.6% (initiated with a Buy at Rosenblatt)
- VFC +1.1% (upgraded to Equal-Weight from Underweight at Morgan Stanley)
- CXW +0.9% (initiated with a Buy at Deutsche Bank)
- MU +0.8% (initiated with Buy ratings at MKM Partners)
- WMT +0.5% (upgraded to Buy from Neutral at BofA/Merrill)